CMS Retires NCD 220.6.11 for FDG PET in Thyroid Cancer — What Billing Teams Need to Know
CMS has officially retired NCD section 220.6.11, the legacy coverage policy governing FDG PET imaging for thyroid cancer, replacing it with the consolidated section 220.6.17 under the broader PET Scans NCD (NCD 302). This change—effective April 10, 2023, and now formally documented in the March 2026 NCD Manual revision—closes out a long-standing administrative loose end that had left some billing teams uncertain about which policy reference to cite. If your revenue cycle team is still citing 220.6.11 in documentation, internal protocols, or payer correspondence, it's time to update those references.
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | FDG PET for Thyroid Cancer (NCD 220.6.11) — RETIRED, replaced by NCD 220.6.17 |
| Policy Code | NCD 302 |
| Change Type | Modified (Section Retired and Consolidated) |
| Effective Date | April 10, 2023 (formally documented March 12, 2026) |
| Impact Level | Medium — operational impact for teams referencing outdated policy citations |
| Specialties Affected | Nuclear Medicine, Radiology, Endocrinology, Oncology, Radiation Oncology |
| Key Action | Update all internal documentation, MAC correspondence templates, and prior auth workflows to reference NCD 220.6.17 instead of 220.6.11. |
What Changed: CMS NCD 220.6.11 for FDG PET Thyroid Cancer Is Now Officially Retired
The Centers for Medicare & Medicaid Services formally retired NCD section 220.6.11—the standalone FDG PET coverage policy for thyroid cancer—and replaced it with section 220.6.17, effective April 3, 2009. Yes, the underlying consolidation happened years ago. What's new as of the March 2026 NCD Manual update is that section 220.6.11 has been physically removed from the NCD Manual, and the revision notice (Rev. 11892) has been formally logged with an issuance date of March 9, 2023, and an implementation date of April 10, 2023.
This matters operationally because CMS policy citations appear in claim documentation, appeal letters, medical necessity arguments, and MAC audit responses. Any billing team or compliance department that built workflows around citing 220.6.11 is now referencing a section that no longer exists in the NCD Manual. That's a documentation gap that can create friction in audits or denials management.
The authoritative reference for FDG PET in thyroid cancer is now NCD §220.6.17, accessible under the PET Scans NCD at the CMS Medicare Coverage Database.
Understanding the NCD 302 Policy Structure for PET Imaging
NCD 302 is CMS's master policy for Positron Emission Tomography (PET) scans. Rather than maintaining dozens of separate, disease-specific coverage policies, CMS has consolidated PET coverage determinations into a single NCD (§220.6) with subsections for specific clinical indications. The retirement of 220.6.11 is part of that long-running consolidation effort.
Under this structure, §220.6.17 now governs the full scope of FDG PET coverage for oncologic indications—including thyroid cancer—along with documentation requirements, covered clinical scenarios, and non-covered uses. Billing teams managing FDG PET claims for thyroid cancer patients must reference §220.6.17 when documenting medical necessity, responding to claim denials, or preparing appeal submissions.
This benefit category falls under Diagnostic Tests (other) for Medicare purposes. That classification affects how claims are processed, which benefit limits apply, and how cost-sharing is calculated for beneficiaries.
Why the 2026 Manual Revision Matters Even Though the Change Is Older
It's a fair question: if the effective date of this consolidation was April 3, 2009, and the implementation notice went out in early 2023, why does the March 2026 manual revision matter to your billing team?
Three reasons:
First, MAC audit documentation. Medicare Administrative Contractors (MACs) reference the current NCD Manual when adjudicating claims and conducting post-payment reviews. If your supporting documentation cites 220.6.11, an auditor reviewing the current manual won't find it—and that inconsistency can trigger additional scrutiny.
Second, appeals and redeterminations. When you file a redetermination or ALJ appeal for a denied FDG PET claim, citing a retired policy section weakens your argument. Your appeal should cite §220.6.17 directly, with a cross-reference to NCD 302.
Third, compliance documentation. If your compliance team maintains a policy reference library or internal coverage determination summaries, those documents need to reflect the current NCD Manual. Retaining retired section references creates compliance exposure, particularly during CMS audits or OIG reviews.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The policy document for NCD 302 (version 302-v3) does not list specific CPT or HCPCS codes in this retirement notice. Coverage criteria, applicable procedure codes, and diagnosis code requirements for FDG PET in thyroid cancer are governed by NCD §220.6.17—the active replacement section. Billing teams should consult §220.6.17 directly for the authoritative code list.
CMS's cross-reference points to the full PET Scans NCD at the Medicare Coverage Database. That document contains the complete list of covered and non-covered indications, applicable procedure codes, and diagnosis requirements for FDG PET across all oncologic indications.
No specific CPT, HCPCS, or ICD-10 codes are listed in this retirement notice. Do not rely on this policy document alone for code-level billing guidance—reference NCD §220.6.17 for current code applicability.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Update your policy reference library immediately. Remove or archive any internal documentation that cites NCD §220.6.11 as an active coverage policy. Replace those citations with §220.6.17 and note the cross-reference to NCD 302. If you maintain a payer policy matrix or coverage determination cheat sheet, this is the section to update first. |
| 2 | Audit your denial appeal templates. Pull any standard appeal or redetermination letter templates your team uses for FDG PET denials in thyroid cancer cases. If those templates cite §220.6.11, revise them before your next appeal submission. Appeals that reference retired policy sections can be dismissed or deprioritized during administrative review. |
| 3 | Verify MAC LCD alignment. Your regional MAC may have a Local Coverage Determination (LCD) that supplements or further defines coverage for FDG PET in thyroid cancer beyond the NCD. Check your MAC's LCD library to confirm whether their current LCD references §220.6.17 and whether any coding or documentation requirements differ from the national policy. |
| 4 | Brief your clinical documentation team. Physicians and mid-level providers who write medical necessity documentation for FDG PET orders should be aware that the governing policy has changed citation. While the clinical coverage criteria under §220.6.17 may not have changed substantially, the policy reference they include in documentation should reflect the current section. |
| 5 | Check your clearinghouse or billing software. Some practice management and billing platforms include built-in payer policy references or medical necessity checking tools. If yours references CMS NCD sections, confirm that the system reflects the retirement of 220.6.11 and routes FDG PET thyroid claims to §220.6.17 criteria. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.